Abstract:AIM: β-Arrestin-1 is an adaptor protein essential in G-protein-coupled receptor signaling and function. Recently, a mechanism by which β-arrestin-1 acted as a scaffolding molecule that regulated signaling pathways of receptor tyrosine kinases was discovered. The goal of this study is to determine the roles of β-arrestin-1 in RON-activated MAP kinase signaling that regulates tumorigenic activities of colon cancer cells. METHODS: Immunohistochemistry of tumor tissue arrays was used to determine RON and β-arrestin-1 expression. Immunoprecipitation and Western blotting were used to determine protein interaction and phosphorylation. Specific siRNA was used to silence β-arrestin-1 gene expression. Cell growth, transformation, and migration were determined by proliferation, focus formation and migration assays. RESULTS: Overexpression of RON (52/88 cases, 59.1%) in primary colon cancer samples was significantly matched with β-arrestin-1 expression. In 52 samples with RON overexpression, β-arrestin-1 was co-expressed in 41 cases (46.6%). In colon cancer HT-29 and other cells, β-arrestin-1 formed a signaling protein complex with RON and c-Src. RON-mediated dephosphorylation of β-arrestin-1 at Ser-412 increased their interaction. Silencing of β-arrestin-1 gene expression by siRNA techniques impaired RON-mediated Erk1/2 phosphorylation but had no effect on AKT phosphorylation. The β-arrestin-1 gene disruption also blocked oncogenic RON160- mediated cellular transformation in rodent fibroblast and colonic epithelial cells. Moreover, silencing β-arrestin-1 gene expression significantly reduced RON agonistic mAb Zt/c1-induced colon cancer cell proliferation but not migration. CONCLUSION: β-Arrestin-1 was selectively involved in RON-transduced signals. The requirement of β-arrestin-1 in MAP kinase signaling shed light on the mechanisms by which RON regulated malignancy of colon cancer cells. © 2010 MedUnion Press - http://www.mupnet.com.

ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2

ARF regulates the stability of p16 protein via REGγ-dependent proteasome degradation.

Progress in the Tumor Suppressor, ARF

The ARF tumor suppressor: Structure, functions and status in cancer

Oncogenes & Tumor Suppressors ARF Regulates the Stability of p 16 Protein Via REG g-Dependent Proteasome Degradation

Deletion of RDINK4/ARF enhancer: A novel mutation to “inactivate” the INK4-ARF locus

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Data from ARF Regulates the Stability of p16 Protein Via REGγ-Dependent Proteasome Degradation

P14arf Interacts with E2F Factors to Form P14arf–e2f/partner‐dna Complexes Repressing E2F‐dependent Transcription

Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function

MDM2-Mediated Degradation of p14ARF: A Novel Mechanism to Control ARF Levels in Cancer Cells

P14ARF: The Absence that Makes the Difference

ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress.

β-Arrestin-1-dependent activation of extracellular signal-regulated kinases in RON receptor-mediated tumorigenic activities in colon cancer cells

Loss of p19(Arf) facilitates the angiogenic switch and tumor initiation in a multi-stage cancer model via p53-dependent and independent mechanisms

Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis

Differential Effects on ARF Stability by Normal Versus Oncogenic Levels of C-Myc Expression.

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

Loss Of Arf Sensitizes Transgenic Braf(V600e) Mice To Uv-Induced Melanoma Via Suppression Of Xpc

Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation.